COMPARE · Data as of August 14, 2026
ETON vs LLY
Verdict: Side-by-side breakdown using the Bull Rankings model. ETON scored 72.0, LLY scored 70.9 — ETON leads.
Compare another set
ETON
Eton Pharmaceuticals, Inc.
72
$58.86 · $1.7B
fundamentals as of
Score gap
1.1
ETON leads
LLY
Eli Lilly and Company
70.9
$1,180.16 · $1.1T
fundamentals as of
The model, pillar by pillar (0–100 each)
ETON
stronger →← stronger
LLY
76
Qualityreturns · margins · balance sheet
73
100
Growthrevenue & earnings expansion
97
50
Valuevaluation vs sector peers
50
ETON is stronger on 2 of 3 pillars.
Fundamentals, head-to-head
ETON
LLY
$15mC-
FCF
$13.6bA-
+81.5%A
Rev
+49.6%A
1.02C
D/E
1.62C
150.9xD
P/E
39.7xC
1.40B
PEG
1.49B
Winner per row is the stronger grade in our model; a tie or a missing value shows no highlight.
Valuation · DCF cross-check
ETON
LLY
335% above
Price vs fair valuelower is cheaper
100% above
~54%/yr
Growth the price implies10-yr FCF · lower = less priced in
~32%/yr
-83%
1-yr DCF upside
-62%
-77%
5-yr DCF upside
-50%
-65%
10-yr DCF upside
-23%
The DCF is a cross-check on intrinsic value, separate from the quality-growth score above.
Model signals
ETON
Why this score
- Short track record
LLY
Why this score
- Raising its dividend
- Short track record
The companies
ETONEton Pharmaceuticals, Inc.
Why now
Drug Manufacturers - Specialty & Generic · market cap $1.7b. Trading near 52-week high of $59.69 — momentum setup, limited technical margin of safety. Revenue growing +81% — in hypergrowth territory. 3 sell-side analysts rate this a Strong Buy with a mean 1-yr target of $62.33 (implying +6% upside).
Moat
Net margin 12% beats the market median by a meaningful margin — the company is keeping more of every revenue dollar than the average S&P constituent. ROE 27% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which. FCF converts 116% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined.
Risk
Trailing P/E 150.9x prices in sustained high growth — any quarter that disappoints triggers sharp re-rating. Trading within 1% of the 52-week high — limited technical margin of safety; a momentum reversal would test conviction. P/S 15.9x embeds aggressive forward growth — disappointing top-line guidance would compress the multiple hard.
LLYEli Lilly and Company
Why now
Drug Manufacturers - General · market cap $1.1T. 6% off the 52-week high of $1249.45. Revenue growing +50% — in hypergrowth territory. 27 sell-side analysts rate this a Buy with a mean 1-yr target of $1,299 (implying +10% upside).
Moat
Net margin 34% is exceptional — pricing-power territory rare outside premium software, branded staples, and specialty pharma. ROE 79% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which. $1.1T market cap places it among the largest companies in the sector — distribution, R&D, and customer-acquisition costs amortize across a base peers can't replicate.
Risk
Trailing P/E 40x sits well above the S&P median (~20x) — multiple compression is a real risk if revenue growth decelerates. P/S 13.2x embeds aggressive forward growth — disappointing top-line guidance would compress the multiple hard. Trial-readout binary — late-stage clinical trials carry approve/reject outcomes that swing valuation 30%+; the equity is effectively a portfolio of these binary events, not a steady cash-flow business.
Verdict — model-derived comparison
Generating verdict… typically 5–10 seconds
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See terms and methodology for full disclosures.
Where ETON and LLY diverge
On the headline score the gap is 1.1 points in favor of ETON. The widest single difference is Growth, where ETON leads by 3.0 points.
- GrowthETON 100.0 · LLY 97.0ETON +3.0
- QualityETON 75.6 · LLY 73.1level
- ValueETON 50.0 · LLY 50.4level
Pillars run 0–100 against sector peers, so a score is a statement about a company relative to its own industry rather than to the other name here. A wide Value gap usually means the market already prices the difference in quality or growth — which is the trade-off this comparison comes down to.